Ranbaxy's 7 ARVs on pre-qualification list of WHO

Ranbaxy Laboratories today announced that the Geneva-based World Health Organisation (WHO) has included seven anti-retrovirals (ARVs) of the company in its pre-qualification list.

According to a release issued by the company to the BSE today, the products approved by WHO are Lamivudine 150 mg+Nevirapine 200mg + Stavudine 40 mg tablets, Lamivudine 150 mg+Nevirapine 200mg + Stavudine 30 mg tablets, Lamivudine 150 mg+Stavudine 40 mg tablets,
Lamivudine 150 mg+Stavudine 30 mg tablets, Lamivudine 150 mg+Zidovudine 300 mg tablets, Lamivudine 150 mg tablets, and
Zidovudine 300 mg tablets.

Brian Tempest, CEO & MD of Ranbaxy, said: "We are delighted to have our ARVs on the WHO list. This is a significant step forward in Ranbaxy's endeavour to make high quality, cost-effective ARVs available to HIV patients around the world. This, along with our USFDA approvals, will ensure that HIV patients have access to quality generic ARVs, irrespective of the funding programme in their country."